Evidence map›Paper›PMID 42233108›Full record

ArticleMolecular therapy. Nucleic acids2026

Exploration of miR-326 delivery via biocompatible polymeric nanoparticles in medulloblastoma: A preliminary study.

Elena Splendiani, Gabriele Maiorano, Zaira Spinello, Davide Vecchiotti, Giorgia Gugliuzza, Marta Moretti, Angela Asquino, Mariapaola Izzo, Agnese Po, Nicole Feverati and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Elena SplendianiDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Gabriele MaioranoNanotechnology Institute, CNR-NANOTEC, c/o Campus Ecotekne Monteroni Street, 73100 Lecce, Italy.
Zaira SpinelloDepartment of Life Sciences, Health and Health Professions, Link Campus University, Via del Casale di San Pio V, 44 00165 Rome, Italy.
Davide VecchiottiDepartment of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, 67100 L'Aquila, Italy.
Giorgia GugliuzzaDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Marta MorettiDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Angela AsquinoDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Mariapaola IzzoDepartment of Molecular Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Agnese PoDepartment of Radiological, Oncological & Pathological Sciences, La Sapienza University of Rome, 00161 Rome, Italy.
Nicole FeveratiDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Tiziana RaiaDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Zein Mersini BesharatDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Daniela VerzellaDepartment of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, 67100 L'Aquila, Italy.
Stefania MardenteDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Alessandra ZicariDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Giuseppe CiccarellaNanotechnology Institute, CNR-NANOTEC, c/o Campus Ecotekne Monteroni Street, 73100 Lecce, Italy.
Anna CitarellaDepartment of Life Sciences, Health and Health Professions, Link Campus University, Via del Casale di San Pio V, 44 00165 Rome, Italy.
Francesca ZazzeroniDepartment of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, 67100 L'Aquila, Italy.
Enrico De SmaeleDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Mary Anna VenneriDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.
Angela MastronuzziDepartment of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Bambino Gesù Children's Hospital, Rome, Italy.
Giuseppe GigliNanotechnology Institute, CNR-NANOTEC, c/o Campus Ecotekne Monteroni Street, 73100 Lecce, Italy.
Adriano AngelucciDepartment of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, 67100 L'Aquila, Italy.
Giuseppina CatanzaroDepartment of Life Sciences, Health and Health Professions, Link Campus University, Via del Casale di San Pio V, 44 00165 Rome, Italy.
Ilaria Elena PalamàNanotechnology Institute, CNR-NANOTEC, c/o Campus Ecotekne Monteroni Street, 73100 Lecce, Italy.
Elisabetta FerrettiDepartment of Experimental Medicine, La Sapienza University of Rome, 00161 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs play a crucial role in tumorigenesis, functioning as oncogenes or tumor-suppressors while orchestrating the differentiation states of cancer cells. In medulloblastoma, the most common malignant pediatric brain tumor, the downregulation of miR-326 is associated with a loss of tumor suppression that leads to uncontrolled proliferation and survival or de-differentiation. In this study, we explore an innovative approach for microRNA delivery using polycaprolactone/chitosan-based nanoparticles. We evaluate the biocompatibility of the nanocarrier in medulloblastoma cell lines and report results on

Indexed as

medulloblastomamicroRNAMT: delivery strategiesnanoparticlespolycaprolactone/chitosanRNA delivery

Identifiers

PMID42233108
PMCPMC13223927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.